1. Mangual-PĂ©rez, D., et al., Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management. JAAOS Global Research & Reviews, 2022. 6(7): p. e22.00055.
2. Balu, A., et al., Medical Cannabis Certification Is Associated With Decreased Opiate Use in Patients With Chronic Pain: A Retrospective Cohort Study in Delaware. Cureus, 2021. 13(12): p. e20240.
3. Whiting, P.F., et al., Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 2015. 313(24): p. 2456-2473.
4. Vučković, S., et al., Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol, 2018. 9: p. 1259.
5. Nagarkatti, P., et al., Cannabinoids as novel anti-inflammatory drugs. Future Med Chem, 2009. 1(7): p. 1333-49.
6. Review: Weak evidence of benefits of cannabis for chronic neuropathic pain; moderate to weak evidence of adverse effects. Annals of Internal Medicine, 2017. 167(12): p. JC62.
7. MĂĽcke, M., et al., Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev, 2018. 3(3): p. Cd012182.
8. Nugent, S.M., et al., The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. Ann Intern Med, 2017. 167(5): p. 319-331.
9. Johnson, J.R., et al., Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage, 2010. 39(2): p. 167-79.
10. Shi, Y., Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend, 2017. 173: p. 144-150.
11. Bradford, A.C., et al., Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. JAMA Intern Med, 2018. 178(5): p. 667-672.
12. Piper, B.J., et al., Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. Journal of Psychopharmacology, 2017. 31(5): p. 569-575.
13. Vigil, J.M., et al., Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study. PLOS ONE, 2017. 12(11): p. e0187795.
14. Malik Z, Baik D, Schey R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep 2015; 17: p. 429.
15. Amato L, Davoli M, Minozzi S, et al. Systematic reviews on therapeutic efficacy and safety of Cannabis (including extracts and tinctures) for patients with multiple sclerosis, chronic neuropathic pain, dementia and Tourette syndrome, HIV/AIDS, and cancer receiving chemotherapy. Roma, Italy: Department of Epidemiology Lazio Regional Health Service, 2016.
16. Musty RE, Rossi R. Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. Journal of Cannabis Therapeutics 2001; 1: p. 29–56.
17. Smith LA, Azariah F, Lavender VTC, et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev, 2015; (11): p. CD009464.
18. Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician 2018; 64: p. 111–120.
19. Whiting PF, Wolff RF, Deshpande S, et al., Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 2015. 313: p. 2456-2473.
20. Phillips RS, Friend AJ, Gibson F, et al: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood, 2016. Cochrane Database Syst Rev 2: p. CD007786.
21. Bar-Lev Schleider L, Mechoulam R, Lederman V, et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 2018; 49: p. 37–43.
22. Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011; 22: p. 2086–2093.
23. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105: p. 1–25.
24. Barann M, Molderings G, Bruss M et al.. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 2002;137: p. 589–596.
25. Kvamme, S.L., et al., Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample. Harm Reduction Journal, 2021. 18(1): p. 72.
26. Arellano, A.L., et al., Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. CNS Neurol Disord Drug Targets, 2017. 16(5): p. 554-566.
27. Anderson, G.D. and L.N. Chan, Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clin Pharmacokinet, 2016. 55(11): p. 1353-1368.
28. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2017. 2(1): p. 139-154.
29. Ebbert, J.O., E.L. Scharf, and R.T. Hurt, Medical Cannabis. Mayo Clin Proc, 2018. 93(12): p. 1842-1847.
30. Zou, S. and U. Kumar, Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci, 2018. 19(3).
31. Basavarajappa, B.S., Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett, 2007. 14(3): p. 237-46.